Beam looks to accelerated approval for AATD base editing after promising updatenews2026-03-25T15:31:38+00:00March 25th, 2026|Endpoints News|
Boehringer Ingelheim plans for dealmaking and R&D spending amid US price pressurenews2026-03-25T15:14:06+00:00March 25th, 2026|Endpoints News|
Novo reports more triple-G data from China; Grifols plots IPO for biopharma unitnews2026-03-25T14:32:11+00:00March 25th, 2026|Endpoints News|
Microneedle vaccine patch company raises $50M for pivot to GLP-1 deliverynews2026-03-25T13:00:28+00:00March 25th, 2026|Endpoints News|
Maze meets own expectations in Phase 2 kidney disease trial in the same arena as Vertexnews2026-03-25T11:02:18+00:00March 25th, 2026|Endpoints News|
Merck to buy Terns for $6.7B, taking a leukemia drug that could challenge Novartis’ Scemblixnews2026-03-25T10:47:34+00:00March 25th, 2026|Endpoints News|
Gilgamesh’s psychedelics pipeline gets $60M backing after AbbVie dealnews2026-03-25T10:00:55+00:00March 25th, 2026|Endpoints News|
Ocugen heads to Phase 3 with gene therapy for geographic atrophynews2026-03-24T15:40:16+00:00March 24th, 2026|Endpoints News|
Lessons from the last health tech revolutionnews2026-03-24T15:23:45+00:00March 24th, 2026|Endpoints News|
FDA warns ImmunityBio over misleading podcast with Patrick Soon-Shiongnews2026-03-24T15:10:14+00:00March 24th, 2026|Endpoints News|
